Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-06-18
1995-12-05
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31415
Patent
active
RE0351121
ABSTRACT:
Compositions for treating tissue damage from ischemia contain PBN, or active derivatives thereof, which are active during ischemia in preventing ATP depletion of the cells which predisposes them to subsequent injury during reperfusion, and which are active during reperfusion as oxygen radical scavengers, in a suitable pharmaceutical carrier for systemic or local administration, especially to the CNS, spinal column and eyes. Based on animal studies, the dosage for treating damage due to stroke is in the range of 10 to 300 mg/kg. Similar dosages are useful in treating damage resulting from free radical generation during inflammation, either as a product of infection or exposure to inflammatory agents or abusive agents, including drugs and alcohol.
REFERENCES:
patent: 3296145 (1967-01-01), Findlam et al.
patent: 3849934 (1974-11-01), Doischner et al.
patent: 4153722 (1979-05-01), Campbell et al.
patent: 4197314 (1980-04-01), Campbell et al.
patent: 4214003 (1980-07-01), Campbell et al.
patent: 4224340 (1980-09-01), Campbell et al.
patent: 4870002 (1989-09-01), Kiel
Novelli et al., Oxygen Free Radicals in Shock, Int. Work-Shop, Florence 1985, pp. 119-124 (Karger, Basel 1986).
Hearse et al., Circulation Research, vol. 60, No. 3, pp. 375-383 (Mar. 1987).
Yanev et al., Oxygen Free Radicals in Shock, Int. Work-Shop, Florence 1985, pp. 193-196 (Karger, Basel 1986).
Ilieva et al., Neurosciences, vol. 12, pp. 223-227.
Chiu et al., Transplantation Proceedings, vol. XIX, No. 1, pp. 1077-1079, (Feb. 1987).
Baethmann et al., Critical Care Medicine, vol. 16, No. 10, pp. 972-977 (Oct. 1988).
K. A. Hossman, Critical Care Medicine, vol. 16, No. 10, pp. 964-971 (Oct. 1988).
Lars Ernster, Critical Care Medicine, vol. 16, No. 10, pp. 947-953 (Oct. 1988).
B. K. Siesjo, Critical Care Medicine, vol. 16, No. 11, pp. 954-963 (Oct. 1988).
Hall et al., J. of Neurotrauma, vol. 6, 3, pp. 169-176 (1989).
Edward D. Hall, Critical Care Clinics, vol. 5, No. 4, pp. 793-805 (Oct. 1989).
Hamburger et al., Circulatory Shock, 29, pp. 329-334 (1989).
McKechnie et al., Circulatory Shock, 19, pp. 429-439 (1986).
Joe McCord, The New England Journ. of Med., vol. 312, No. 3, pp. 159-163 (Jan. 1985).
Chandler et al., J. Pharm. Methods, 14, pp. 137-146 (1985).
Petkova et al., Agressologie 28, 8, pp. 833-834 (1987).
Hearse et al., J. Mol. Cell. Cardiol. 20, 223-233 (1988).
Bolli et al., J. Clin. Invest. 82, pp. 476-485 (Aug. 1988).
Weglickl et al., Oxy-Radicals in Molecular Biology and Pathology, pp. 357-364, (Proceedings of an Upjohn-UCLA Symposium held at Park City, Utah, Jan. 24-30, 1988) Editor: Alan R. Liss, Inc., N.Y.
E. Masini et al., Agents and Actions, vol. 27, 1/2 pp. 154-157 (1989).
Novelli et al., Free Radicals in Liver Injury, pp. 225-228 (IRL Press, Oxford, England).
Carney John M.
Floyd Robert A.
Henley III Raymond
MacMillan Keith
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
LandOfFree
Phenyl butyl nitrone compositions and methods for treatment of o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenyl butyl nitrone compositions and methods for treatment of o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenyl butyl nitrone compositions and methods for treatment of o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1365500